SCHWARZ REPORTS RESULTS OF PAIN DRUG TRIAL

A A

Schwarz Pharma has announced that Phase III data of its Lacosamide drug to treat epilepsy showed clinically relevant and statistically significant positive results. The drug was well-tolerated, and the data from the trial confirms the results seen in the company's Phase II Lacosamide program.

The drug has also been shown to be a safe and effective treatment for diabetic neuropathic pain.